Compare ADMA Biologics Inc (ADMA) vs Zillow Group Inc Class C (Z) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Zillow Group (Z) trades at $32.96, down 1.41% on the day, amid mixed technical signals and ongoing class action lawsuits. The company shows improving fundamentals with revenue growing to $2.58B in 2025 and net income turning positive at $23M, though valuation remains elevated with a P/E of 131.84. Analyst consensus is a Buy with a $63 price target, but legal overhangs and negative cash flow trends present headwinds.

The outlook is cautiously optimistic given strong revenue growth and analyst support, but investment opportunities are tempered by legal risks and high valuation multiples. Key risks include lawsuit outcomes, competitive pressures, and cash flow sustainability, requiring careful monitoring of upcoming Q2 2026 earnings on August 5 for confirmation of profit trajectory.